Skip to content
Open access · CC-BY via OpenAlex

One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant metformin

Javier Abel Menéndez, Jorge Joven

Aging · 2013 · ▲ 21 citations

Abstract

The gerosuppressant metformin operates as an efficient inhibitor of the mTOR(definition)/S6K1 gerogenic pathway due to its ability to ultimately activate the energy-sensor AMPK. If an aging-related decline in the AMPK sensitivity to cellular stress is a crucial event for mTOR-driven aging and aging-related diseases, including cancer, unraveling new proximal causes through which AMPK activation endows its gerosuppressive effects may offer not only a better understanding of metformin function but also the likely possibility of repositioning our existing gerosuppressant drugs. Here we provide our perspective on recent findings suggesting that de novo biosynthesis of purine nucleotides, which is based on the metabolism of one-carbon compounds, is a new target for metformin's actions at the crossroads of aging and cancer.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.18632/aging.100523
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Menéndez, J.A., &amp; Joven, J. (2013). One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant metformin. <em>Aging</em>. https://doi.org/10.18632/aging.100523
Vancouver
Menéndez JA, Joven J. One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant metformin. Aging. 2013. doi:10.18632/aging.100523.
BibTeX
@article{javier2013Onecar, title = {One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant metformin}, author = {Javier Abel Menéndez and Jorge Joven}, journal = {Aging}, year = {2013}, doi = {10.18632/aging.100523}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings